Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):1082–1093. doi: 10.1128/aac.41.5.1082

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

S M Daluge 1, S S Good 1, M B Faletto 1, W H Miller 1, M H St Clair 1, L R Boone 1, M Tisdale 1, N R Parry 1, J E Reardon 1, R E Dornsife 1, D R Averett 1, T A Krenitsky 1
PMCID: PMC163855  PMID: 9145874

Abstract

1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with a unique biological profile giving potent, selective anti-human immunodeficiency virus (HIV) activity. 1592U89 was selected after evaluation of a wide variety of analogs containing a cyclopentene substitution for the 2'-deoxyriboside of natural deoxynucleosides, optimizing in vitro anti-HIV potency, oral bioavailability, and central nervous system (CNS) penetration. 1592U89 was equivalent in potency to 3'-azido-3'-deoxythymidine (AZT) in human peripheral blood lymphocyte (PBL) cultures against clinical isolates of HIV type 1 (HIV-1) from antiretroviral drug-naive patients (average 50% inhibitory concentration [IC50], 0.26 microM for 1592U89 and 0.23 microM for AZT). 1592U89 showed minimal cross-resistance (approximately twofold) with AZT and other approved HIV reverse transcriptase (RT) inhibitors. 1592U89 was synergistic in combination with AZT, the nonnucleoside RT inhibitor nevirapine, and the protease inhibitor 141W94 in MT4 cells against HIV-1 (IIIB). 1592U89 was anabolized intracellularly to its 5'-monophosphate in CD4+ CEM cells and in PBLs, but the di- and triphosphates of 1592U89 were not detected. The only triphosphate found in cells incubated with 1592U89 was that of the guanine analog (-)-carbovir (CBV). However, the in vivo pharmacokinetic, distribution, and toxicological profiles of 1592U89 were distinct from and improved over those of CBV, probably because CBV itself was not appreciably formed from 1592U89 in cells or animals (<2%). The 5'-triphosphate of CBV was a potent, selective inhibitor of HIV-1 RT, with Ki values for DNA polymerases (alpha, beta, gamma, and epsilon which were 90-, 2,900-, 1,200-, and 1,900-fold greater, respectively, than for RT (Ki, 21 nM). 1592U89 was relatively nontoxic to human bone marrow progenitors erythroid burst-forming unit and granulocyte-macrophage CFU (IC50s, 110 microM) and human leukemic and liver tumor cell lines. 1592U89 had excellent oral bioavailability (105% in the rat) and penetrated the CNS (rat brain and monkey cerebrospinal fluid) as well as AZT. Having demonstrated an excellent preclinical profile, 1592U89 has progressed to clinical evaluation in HIV-infected patients.

Full Text

The Full Text of this article is available as a PDF (377.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Averett D. R. Anti-HIV compound assessment by two novel high capacity assays. J Virol Methods. 1989 Mar;23(3):263–276. doi: 10.1016/0166-0934(89)90159-6. [DOI] [PubMed] [Google Scholar]
  2. Brouwer K. R., St Claire R. L., Lagarde J., Patanella J. E., Walsh J. S., Miwa G. T. The pharmacokinetics of (-)-carbovir in rats. Evidence for nonlinear elimination. Drug Metab Dispos. 1990 Nov-Dec;18(6):1078–1083. [PubMed] [Google Scholar]
  3. Collins J. M., Klecker R. W., Jr, Kelley J. A., Roth J. S., McCully C. L., Balis F. M., Poplack D. G. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther. 1988 May;245(2):466–470. [PubMed] [Google Scholar]
  4. Daluge S. M., Purifoy D. J., Savina P. M., St Clair M. H., Parry N. R., Dev I. K., Novak P., Ayers K. M., Reardon J. E., Roberts G. B. 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590–1603. doi: 10.1128/aac.38.7.1590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davis M. G., Jansen R. W. Inhibition of hepatitis B virus in tissue culture by alpha interferon. Antimicrob Agents Chemother. 1994 Dec;38(12):2921–2924. doi: 10.1128/aac.38.12.2921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dornsife R. E., Averett D. R. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother. 1996 Feb;40(2):514–519. doi: 10.1128/aac.40.2.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dornsife R. E., St Clair M. H., Huang A. T., Panella T. J., Koszalka G. W., Burns C. L., Averett D. R. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother. 1991 Feb;35(2):322–328. doi: 10.1128/aac.35.2.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Du D. L., Volpe D. A., Grieshaber C. K., Murphy M. J., Jr In vitro toxicity of 3'-azido-3'-deoxythymidine, carbovir and 2',3'-didehydro-2',3'-dideoxythymidine to human and murine haematopoietic progenitor cells. Br J Haematol. 1992 Apr;80(4):437–445. doi: 10.1111/j.1365-2141.1992.tb04555.x. [DOI] [PubMed] [Google Scholar]
  9. Faletto M. B., Miller W. H., Garvey E. P., St Clair M. H., Daluge S. M., Good S. S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother. 1997 May;41(5):1099–1107. doi: 10.1128/aac.41.5.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  11. Gadler H. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication. Antimicrob Agents Chemother. 1983 Sep;24(3):370–374. doi: 10.1128/aac.24.3.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Garrett C., Santi D. V. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem. 1979 Nov 1;99(2):268–273. doi: 10.1016/s0003-2697(79)80005-6. [DOI] [PubMed] [Google Scholar]
  13. Ho D. H., Pincus C., Carter C. J., Benjamin R. S., Freireich E. J., Bodey G. P., Sr Distribution and inhibition of adenosine deaminase in tissues of man, rat, and mouse. Cancer Treat Rep. 1980 Apr-May;64(4-5):629–633. [PubMed] [Google Scholar]
  14. Ho H. T., Hitchcock M. J. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 1989 Jun;33(6):844–849. doi: 10.1128/aac.33.6.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Huang S. H., Remmel R. P., Zimmerman C. L. The bioavailability and nonlinear clearance of (-)-carbovir in the rat. Pharm Res. 1991 Jun;8(6):739–743. doi: 10.1023/a:1015850017201. [DOI] [PubMed] [Google Scholar]
  16. Jansen R. W., Johnson L. C., Averett D. R. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother. 1993 Mar;37(3):441–447. doi: 10.1128/aac.37.3.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kavlick M. F., Shirasaka T., Kojima E., Pluda J. M., Hui F., Jr, Yarchoan R., Mitsuya H. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine. Antiviral Res. 1995 Oct;28(2):133–146. doi: 10.1016/0166-3542(95)00044-m. [DOI] [PubMed] [Google Scholar]
  18. Kurtzberg J., Carter S. G. Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro. Exp Hematol. 1990 Nov;18(10):1094–1096. [PubMed] [Google Scholar]
  19. Larder B. A., Chesebro B., Richman D. D. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990 Mar;34(3):436–441. doi: 10.1128/aac.34.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Larder B. A. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 (Suppl 1):S28–S33. [PubMed] [Google Scholar]
  21. Mahony W. B., Domin B. A., Daluge S. M., Miller W. H., Zimmerman T. P. Enantiomeric selectivity of carbovir transport. J Biol Chem. 1992 Oct 5;267(28):19792–19797. [PubMed] [Google Scholar]
  22. Merigan T. C., Skowron G. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Am J Med. 1990 May 21;88(5B):11S–15S. doi: 10.1016/0002-9343(90)90415-a. [DOI] [PubMed] [Google Scholar]
  23. Miller W. H., Daluge S. M., Garvey E. P., Hopkins S., Reardon J. E., Boyd F. L., Miller R. L. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J Biol Chem. 1992 Oct 15;267(29):21220–21224. [PubMed] [Google Scholar]
  24. Paff M. T., Averett D. R., Prus K. L., Miller W. H., Nelson D. J. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob Agents Chemother. 1994 Jun;38(6):1230–1238. doi: 10.1128/aac.38.6.1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Parker W. B., Shaddix S. C., Bowdon B. J., Rose L. M., Vince R., Shannon W. M., Bennett L. L., Jr Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism. Antimicrob Agents Chemother. 1993 May;37(5):1004–1009. doi: 10.1128/aac.37.5.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Parker W. B., White E. L., Shaddix S. C., Ross L. J., Buckheit R. W., Jr, Germany J. M., Secrist J. A., 3rd, Vince R., Shannon W. M. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem. 1991 Jan 25;266(3):1754–1762. [PubMed] [Google Scholar]
  27. Petersen E. A., Ramírez-Ronda C. H., Hardy W. D., Schwartz R., Sacks H. S., Follansbee S., Peterson D. M., Cross A., Anderson R. E., Dunkle L. M. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis. 1995 Mar;171 (Suppl 2):S131–S139. doi: 10.1093/infdis/171.supplement_2.s131. [DOI] [PubMed] [Google Scholar]
  28. Prichard M. N., Shipman C., Jr A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990 Oct-Nov;14(4-5):181–205. doi: 10.1016/0166-3542(90)90001-n. [DOI] [PubMed] [Google Scholar]
  29. Prus K. L., Averett D. R., Zimmerman T. P. Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. 1990 Mar 15;50(6):1817–1821. [PubMed] [Google Scholar]
  30. Reardon J. E., Furfine E. S., Cheng N. Human immunodeficiency virus reverse transcriptase. Effect of primer length on template-primer binding. J Biol Chem. 1991 Jul 25;266(21):14128–14134. [PubMed] [Google Scholar]
  31. Reardon J. E. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry. 1992 May 12;31(18):4473–4479. doi: 10.1021/bi00133a013. [DOI] [PubMed] [Google Scholar]
  32. Remington K. M., Chesebro B., Wehrly K., Pedersen N. C., North T. W. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol. 1991 Jan;65(1):308–312. doi: 10.1128/jvi.65.1.308-312.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  34. Rocancourt D., Bonnerot C., Jouin H., Emerman M., Nicolas J. F. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol. 1990 Jun;64(6):2660–2668. doi: 10.1128/jvi.64.6.2660-2668.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sherman P. A., Fyfe J. A. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989 Aug 1;180(2):222–226. doi: 10.1016/0003-2697(89)90420-x. [DOI] [PubMed] [Google Scholar]
  36. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis. 1995 Mar;171 (Suppl 2):S113–S117. doi: 10.1093/infdis/171.supplement_2.s113. [DOI] [PubMed] [Google Scholar]
  37. Spector T., Jones T. E., Beacham L. M., 3rd Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase. Biochem Pharmacol. 1983 Sep 1;32(17):2505–2509. doi: 10.1016/0006-2952(83)90010-2. [DOI] [PubMed] [Google Scholar]
  38. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  39. Thedford R., Leyimu E. O., Thornton D. L., Mehta R. Cytotoxicity of N6-cycloalkylated adenine and adenosine analogs to mouse hepatoma cells. Exp Cell Biol. 1989;57(2):53–59. doi: 10.1159/000163508. [DOI] [PubMed] [Google Scholar]
  40. Tisdale M., Alnadaf T., Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997 May;41(5):1094–1098. doi: 10.1128/aac.41.5.1094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Upton R. A. Simple and reliable method for serial sampling of blood from rats. J Pharm Sci. 1975 Jan;64(1):112–114. doi: 10.1002/jps.2600640123. [DOI] [PubMed] [Google Scholar]
  43. Van Draanen N. A., Tisdale M., Parry N. R., Jansen R., Dornsife R. E., Tuttle J. V., Averett D. R., Koszalka G. W. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother. 1994 Apr;38(4):868–871. doi: 10.1128/aac.38.4.868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Vince R., Hua M., Brownell J., Daluge S., Lee F. C., Shannon W. M., Lavelle G. C., Qualls J., Weislow O. S., Kiser R. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem Biophys Res Commun. 1988 Oct 31;156(2):1046–1053. doi: 10.1016/s0006-291x(88)80950-1. [DOI] [PubMed] [Google Scholar]
  45. Wainberg M. A., Salomon H., Gu Z., Montaner J. S., Cooley T. P., McCaffrey R., Ruedy J., Hirst H. M., Cammack N., Cameron J. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995 Apr;9(4):351–357. [PubMed] [Google Scholar]
  46. Walsh J. S., Patanella J. E., Unger S. E., Brouwer K. R., Miwa G. T. The metabolism and excretion of carbovir, a carbocyclic nucleoside, in the rat. Drug Metab Dispos. 1990 Nov-Dec;18(6):1084–1091. [PubMed] [Google Scholar]
  47. Yarchoan R., Pluda J. M., Thomas R. V., Mitsuya H., Brouwers P., Wyvill K. M., Hartman N., Johns D. G., Broder S. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet. 1990 Sep 1;336(8714):526–529. doi: 10.1016/0140-6736(90)92085-v. [DOI] [PubMed] [Google Scholar]
  48. Zimmerman T. P., Mahony W. B., Prus K. L. 3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem. 1987 Apr 25;262(12):5748–5754. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES